+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue, Primary antibody: P11931(MAVS Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P11931(MAVS Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

MAVS (Mitochondrial Antiviral Signaling Protein), also known as IPS-1. VISA, or Cardif, is a critical adaptor protein in the innate immune response against RNA viruses. Located on the outer mitochondrial membrane, MAVS acts as a downstream signaling hub for retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), which detect viral RNA in the cytoplasm. Upon RLR activation, MAVS forms prion-like aggregates that recruit signaling complexes, triggering the activation of transcription factors NF-κB and IRF3. This leads to the production of type I interferons (IFNs) and proinflammatory cytokines, essential for antiviral defense.

MAVS antibodies are vital tools for studying antiviral signaling pathways. They are widely used in techniques like Western blotting, immunofluorescence, and co-immunoprecipitation to analyze MAVS expression, localization, and interactions with partners like TRAFs, TRIM25. and STING. Researchers also employ MAVS antibodies to investigate its role in diseases, including viral infections, autoimmune disorders, and cancer, where dysregulated MAVS signaling may contribute to pathogenesis. Polyclonal and monoclonal antibodies targeting specific domains (e.g., CARD, transmembrane) help dissect MAVS structure-function relationships. Validation using MAVS-knockout cell lines ensures antibody specificity, critical for interpreting experimental results. These antibodies have advanced understanding of mitochondrial-mediated immunity and therapeutic targeting strategies.